A citation-based method for searching scientific literature

K White, K Connor, J Clerkin, B M Murphy, M Salvucci, A C O'Farrell, M Rehm, D O'Brien, J H M Prehn, S P Niclou, M L M Lamfers, M Verreault, A Idbaih, R Verhaak, A Golebiewska, A T Byrne. Ann Oncol 2020
Times Cited: 8







List of co-cited articles
40 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.
Cyril Neftel, Julie Laffy, Mariella G Filbin, Toshiro Hara, Marni E Shore, Gilbert J Rahme, Alyssa R Richman, Dana Silverbush, McKenzie L Shaw, Christine M Hebert,[...]. Cell 2019
399
37

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
37

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
37

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Patrick Y Wen, Michael Weller, Eudocia Quant Lee, Brian M Alexander, Jill S Barnholtz-Sloan, Floris P Barthel, Tracy T Batchelor, Ranjit S Bindra, Susan M Chang, E Antonio Chiocca,[...]. Neuro Oncol 2020
110
25

Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
Arman Jahangiri, Michael De Lay, Liane M Miller, W Shawn Carbonell, Yu-Long Hu, Kan Lu, Maxwell W Tom, Jesse Paquette, Taku A Tokuyasu, Sean Tsao,[...]. Clin Cancer Res 2013
144
25

Origin of the U87MG glioma cell line: Good news and bad news.
Marie Allen, Mia Bjerke, Hanna Edlund, Sven Nelander, Bengt Westermark. Sci Transl Med 2016
206
25

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.
Olivier Keunen, Mikael Johansson, Anaïs Oudin, Morgane Sanzey, Siti A Abdul Rahim, Fred Fack, Frits Thorsen, Torfinn Taxt, Michal Bartos, Radovan Jirik,[...]. Proc Natl Acad Sci U S A 2011
433
25

Interrogating open issues in cancer precision medicine with patient-derived xenografts.
Annette T Byrne, Denis G Alférez, Frédéric Amant, Daniela Annibali, Joaquín Arribas, Andrew V Biankin, Alejandra Bruna, Eva Budinská, Carlos Caldas, David K Chang,[...]. Nat Rev Cancer 2017
320
25

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Olivier L Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Antoine F Carpentier, Khe Hoang-Xuan, Petr Kavan, Dana Cernea,[...]. N Engl J Med 2014
25

Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas.
Fred Fack, Heidi Espedal, Olivier Keunen, Anna Golebiewska, Nina Obad, Patrick N Harter, Michel Mittelbronn, Oliver Bähr, Astrid Weyerbrock, Linda Stuhr,[...]. Acta Neuropathol 2015
77
25

A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Mark R Gilbert, James J Dignam, Terri S Armstrong, Jeffrey S Wefel, Deborah T Blumenthal, Michael A Vogelbaum, Howard Colman, Arnab Chakravarti, Stephanie Pugh, Minhee Won,[...]. N Engl J Med 2014
25

A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity.
Fadi Jacob, Ryan D Salinas, Daniel Y Zhang, Phuong T T Nguyen, Jordan G Schnoll, Samuel Zheng Hao Wong, Radhika Thokala, Saad Sheikh, Deeksha Saxena, Stefan Prokop,[...]. Cell 2020
183
25

A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo.
Christopher G Hubert, Maricruz Rivera, Lisa C Spangler, Qiulian Wu, Stephen C Mack, Briana C Prager, Marta Couce, Roger E McLendon, Andrew E Sloan, Jeremy N Rich. Cancer Res 2016
247
25

Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.
Jeongwu Lee, Svetlana Kotliarova, Yuri Kotliarov, Aiguo Li, Qin Su, Nicholas M Donin, Sandra Pastorino, Benjamin W Purow, Neil Christopher, Wei Zhang,[...]. Cancer Cell 2006
25

Glioblastoma Model Using Human Cerebral Organoids.
Junko Ogawa, Gerald M Pao, Maxim N Shokhirev, Inder M Verma. Cell Rep 2018
146
25

Management of glioblastoma: State of the art and future directions.
Aaron C Tan, David M Ashley, Giselle Y López, Michael Malinzak, Henry S Friedman, Mustafa Khasraw. CA Cancer J Clin 2020
154
25

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto,[...]. Lancet Oncol 2017
419
25

Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Reatul Karim, Claudio Palazzo, Brigitte Evrard, Geraldine Piel. J Control Release 2016
118
25

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
Wolfgang Wick, Vinay K Puduvalli, Marc C Chamberlain, Martin J van den Bent, Antoine F Carpentier, Lawrence M Cher, Warren Mason, Michael Weller, Shengyan Hong, Luna Musib,[...]. J Clin Oncol 2010
327
25

A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.
Yazmin Odia, Joohee Sul, Joanna H Shih, Teri N Kreisl, John A Butman, Fabio M Iwamoto, Howard A Fine. CNS Oncol 2016
13
25

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, John G Kuhn, Andrew D Norden, Timothy F Cloughesy, H Ian Robins, Frank S Lieberman, Mark R Gilbert, Minesh P Mehta,[...]. Neuro Oncol 2014
97
25

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
David A Reardon, Annick Desjardins, James J Vredenburgh, Sridharan Gururangan, Allan H Friedman, James E Herndon, Jennifer Marcello, Julie A Norfleet, Roger E McLendon, John H Sampson,[...]. J Neurooncol 2010
152
25

Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma.
Surasak Phuphanich, Jeffrey Raizer, Marc Chamberlain, Paola Canelos, Rajesh Narwal, Shengyan Hong, Robert Miday, Minal Nade, Kevin Laubscher. J Neurooncol 2017
11
25


Temozolomide: mechanisms of action, repair and resistance.
Jihong Zhang, Malcolm F G Stevens, Tracey D Bradshaw. Curr Mol Pharmacol 2012
367
25

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
David A Reardon, Louis B Nabors, Warren P Mason, James R Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, Agnieszka Cseh, Yali Fu,[...]. Neuro Oncol 2015
92
25

Lomustine and Bevacizumab in Progressive Glioblastoma.
Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A Brandes, Walter Taal, Julien Domont, Ahmed Idbaih,[...]. N Engl J Med 2017
316
25

Identification of a cancer stem cell in human brain tumors.
Sheila K Singh, Ian D Clarke, Mizuhiko Terasaki, Victoria E Bonn, Cynthia Hawkins, Jeremy Squire, Peter B Dirks. Cancer Res 2003
25

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Henry S Friedman, Michael D Prados, Patrick Y Wen, Tom Mikkelsen, David Schiff, Lauren E Abrey, W K Alfred Yung, Nina Paleologos, Martin K Nicholas, Randy Jensen,[...]. J Clin Oncol 2009
25

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Manfred Westphal, Dana C Hilt, Enoch Bortey, Patrick Delavault, Robert Olivares, Peter C Warnke, Ian R Whittle, Juha Jääskeläinen, Zvi Ram. Neuro Oncol 2003
838
25

A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.
Wolfgang Wick, Harald Fricke, Klaus Junge, Grigory Kobyakov, Tobias Martens, Oliver Heese, Benedikt Wiestler, Maximilian G Schliesser, Andreas von Deimling, Josef Pichler,[...]. Clin Cancer Res 2014
79
25

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Tracy T Batchelor, Elizabeth R Gerstner, Xiaobu Ye, Serena Desideri, Daniel G Duda, David Peereboom, Glenn J Lesser, Sajeel Chowdhary, Patrick Y Wen, Stuart Grossman,[...]. Neuro Oncol 2017
15
25

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sith Sathornsumetee, Annick Desjardins, James J Vredenburgh, Roger E McLendon, Jennifer Marcello, James E Herndon, Alyssa Mathe, Marta Hamilton, Jeremy N Rich, Julie A Norfleet,[...]. Neuro Oncol 2010
156
25

A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Evanthia Galanis, S Keith Anderson, Erin L Twohy, Xiomara W Carrero, Jesse G Dixon, David Dinh Tran, Suriya A Jeyapalan, Daniel M Anderson, Timothy J Kaufmann, Ryan W Feathers,[...]. Cancer 2019
24
25

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
J J Raizer, P Giglio, J Hu, M Groves, R Merrell, C Conrad, S Phuphanich, V K Puduvalli, M Loghin, N Paleologos,[...]. J Neurooncol 2016
34
25

NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
David M Peereboom, Manmeet S Ahluwalia, Xiaobu Ye, Jeffrey G Supko, Sarah L Hilderbrand, Surasak Phuphanich, L Burt Nabors, Myrna R Rosenfeld, Tom Mikkelsen, Stuart A Grossman. Neuro Oncol 2013
55
25

A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.
Yazmin Odia, Fabio M Iwamoto, Argirios Moustakas, Tyler J Fraum, Carlos A Salgado, Aiguo Li, Teri N Kreisl, Joohee Sul, John A Butman, Howard A Fine. J Neurooncol 2016
24
25

Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
Andrew B Lassman, Stephanie L Pugh, Mark R Gilbert, Kenneth D Aldape, Sandrine Geinoz, Jan H Beumer, Susan M Christner, Ritsuko Komaki, Lisa M DeAngelis, Rakesh Gaur,[...]. Neuro Oncol 2015
70
25

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma.
Manfred Westphal, Oliver Heese, Joachim P Steinbach, Oliver Schnell, Gabriele Schackert, Maximilian Mehdorn, Dirk Schulz, Matthias Simon, Uwe Schlegel, Christian Senft,[...]. Eur J Cancer 2015
100
25

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Tracy T Batchelor, Paul Mulholland, Bart Neyns, L Burt Nabors, Mario Campone, Antje Wick, Warren Mason, Tom Mikkelsen, Surasak Phuphanich, Lynn S Ashby,[...]. J Clin Oncol 2013
325
25

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Yuji Piao, Ji Liang, Lindsay Holmes, Amado J Zurita, Verlene Henry, John V Heymach, John F de Groot. Neuro Oncol 2012
152
12

Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression.
Shannon Patricia Fortin Ensign, Ian T Mathews, Marc H Symons, Michael E Berens, Nhan L Tran. Front Oncol 2013
72
12

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.
Quinn T Ostrom, Haley Gittleman, Gabrielle Truitt, Alexander Boscia, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2018
834
12

The guanine nucleotide exchange factor Arhgef7/βPix promotes axon formation upstream of TC10.
Alejandro López Tobón, Megalakshmi Suresh, Jing Jin, Alessandro Vitriolo, Thorben Pietralla, Kerry Tedford, Michael Bossenz, Kristina Mahnken, Friedemann Kiefer, Giuseppe Testa,[...]. Sci Rep 2018
10
12


Indispensable role of STIL in the regulation of cancer cell motility through the lamellipodial accumulation of ARHGEF7-PAK1 complex.
Hideaki Ito, Takumi Tsunoda, Miho Riku, Shingo Inaguma, Akihito Inoko, Hideki Murakami, Hiroshi Ikeda, Michiyuki Matsuda, Kenji Kasai. Oncogene 2020
6
16

The p75 neurotrophin receptor is a central regulator of glioma invasion.
Angela L M Johnston, Xueqing Lun, Jennifer J Rahn, Abdelhamid Liacini, Limei Wang, Mark G Hamilton, Ian F Parney, Barbara L Hempstead, Stephen M Robbins, Peter A Forsyth,[...]. PLoS Biol 2007
112
12

Overcoming therapeutic resistance in glioblastoma: the way forward.
Satoru Osuka, Erwin G Van Meir. J Clin Invest 2017
191
12

Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation.
D W Murray, S Didier, A Chan, V Paulino, L Van Aelst, R Ruggieri, N L Tran, A T Byrne, M Symons. Br J Cancer 2014
20
12

In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme.
Monika A Jarzabek, Peter C Huszthy, Kai O Skaftnesmo, Emmet McCormack, Patrick Dicker, Jochen H M Prehn, Rolf Bjerkvig, Annette T Byrne. Mol Imaging 2013
16
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.